Thyroid hormone replacement approved as diagnostic aid
This article was originally published in Clinica
Executive Summary
Genzyme General's Thyrogen (injectable thyrotropin alpha) has been approved in the US for use in follow-up screening of thyroid cancer patients. The drug, a recombinant form of thyroid stimulating hormone (TSH), allows patients who undergo diagnostic testing for cancer recurrence to avoid side-effects caused by the withdrawal of their hormone supplements, which accompanies testing.